[go: up one dir, main page]

WO2009044294A3 - Means and methods for the treatment of cataract and presbyopia - Google Patents

Means and methods for the treatment of cataract and presbyopia Download PDF

Info

Publication number
WO2009044294A3
WO2009044294A3 PCT/IB2008/003602 IB2008003602W WO2009044294A3 WO 2009044294 A3 WO2009044294 A3 WO 2009044294A3 IB 2008003602 W IB2008003602 W IB 2008003602W WO 2009044294 A3 WO2009044294 A3 WO 2009044294A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
nucleic acid
sequence
seq
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/003602
Other languages
French (fr)
Other versions
WO2009044294A2 (en
Inventor
Karl-Heinz Krause
Lena Serrander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Hopitaux Universitaires De Geneve
Original Assignee
Universite de Geneve
Hopitaux Universitaires De Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve, Hopitaux Universitaires De Geneve filed Critical Universite de Geneve
Publication of WO2009044294A2 publication Critical patent/WO2009044294A2/en
Publication of WO2009044294A3 publication Critical patent/WO2009044294A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an inhibitor of a protein, wherein said protein (i) comprises or consists of the amino acid sequence of SEQ ID NOs: 2 or 4, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NOs: 1 or 3; (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 26, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NO: 25; (iii) is a fragment of the protein according to (i), or has a sequence at least 75% identical with the protein according to (i) or with said fragment of the protein according to (i), and exhibits NADPH oxidase activity; or (iv) is a fragment of the protein according to (ii) or has a sequence at least 75% identical with the protein according to (ii) or with said fragment of the protein according to (ii) and stabilizes said protein exhibiting NADPH oxidase activity; and/or an inhibitor of a nucleic acid, wherein said nucleic (v) comprises or consists of the nucleic acid sequence of SEQ ID NO: 1 or 3, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 2 or 4; (vi) comprises or consists of the nucleic acid sequence of SEQ ID NO: 25, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 26; (vii) is a fragment of the nucleic acid according to (v), or has a sequence at least 75% identical with the nucleic acid according to (v) or with said fragment of the nucleic acid according to (v), and encodes a protein exhibiting NADPH oxidase activity; or (viii) is a fragment of the nucleic acid according to (vi), or has a sequence at least 75% identical with the nucleic acid according to (vi) or with said fragment of the nucleic acid according to (vi), and encodes a protein stabilizing said protein exhibiting NADPH oxidase activity; for treatment and/or prevention of cataract and/or presbyopia. The sequences define NADPH oxidases or a subunit of an NADPH oxidase, respectively. A preferred inhibitor is a siRNA. Also provided are a method of treating cataract and presbyopia, pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.
PCT/IB2008/003602 2007-06-15 2008-06-12 Means and methods for the treatment of cataract and presbyopia Ceased WO2009044294A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94421807P 2007-06-15 2007-06-15
US60/944,218 2007-06-15

Publications (2)

Publication Number Publication Date
WO2009044294A2 WO2009044294A2 (en) 2009-04-09
WO2009044294A3 true WO2009044294A3 (en) 2009-05-22

Family

ID=40403985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003602 Ceased WO2009044294A2 (en) 2007-06-15 2008-06-12 Means and methods for the treatment of cataract and presbyopia

Country Status (1)

Country Link
WO (1) WO2009044294A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988336A (en) * 2012-05-17 2013-03-27 中国人民解放军第二军医大学 Use of TPCK (N-tosyl-L-phenylanyl chloromethyl ketone) in preparation of anti-lenticular opacity products
WO2018078922A1 (en) * 2016-10-24 2018-05-03 国立大学法人福井大学 Preventive agent and therapeutic agent for cataracts, and use of hat inhibitor for production thereof
JP7097850B2 (en) * 2019-04-23 2022-07-08 ジェネシスヘルスケア株式会社 How to determine the risk of hyperopia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119251A2 (en) * 2004-06-04 2005-12-15 University Of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
WO2006040839A1 (en) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Eye drops and kit for treatment of eye disease
US20080275016A1 (en) * 2007-05-03 2008-11-06 Arbiser Jack L Fulvene and fulvalene analogs and their use in treating cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119251A2 (en) * 2004-06-04 2005-12-15 University Of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
WO2006040839A1 (en) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Eye drops and kit for treatment of eye disease
US20080275016A1 (en) * 2007-05-03 2008-11-06 Arbiser Jack L Fulvene and fulvalene analogs and their use in treating cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2005, WAN Y ET AL: "Ultraviolet irradiation activates MAP kinases via redox-sensitive pathways in cultured human lens cells", XP002520973, Database accession no. PREV200600052705 *
DATABASE WPI Week 200630, Derwent World Patents Index; AN 2006-294270, XP002521067 *
INVESTIGATIVE OPHTALMOLOGY & VISULA SCIENCE, vol. 46, no. Suppl. S, 2005, ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, pages 837, ISSN: 0146-0404 *
JIANG QIN ET AL: "UV radiation down-regulates Dsg-2 via Rac/NADPH oxidase-mediated generation of ROS in human lens epithelial cells.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE AUG 2006, vol. 18, no. 2, August 2006 (2006-08-01), pages 381 - 387, XP002520930, ISSN: 1107-3756 *
RAO PONUGOTI VASANTHA ET AL: "Expression of nonphagocytic NADPH oxidase system in the ocular lens.", MOLECULAR VISION 19 FEB 2004, vol. 10, 19 February 2004 (2004-02-19), pages 112 - 121, XP002520931, ISSN: 1090-0535 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents

Also Published As

Publication number Publication date
WO2009044294A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2008104978A3 (en) Novel sirna structures
WO2005028628A3 (en) Modulation of eif4e expression
EA200602191A1 (en) 5.5-DESIGNED-2-AMINO-4-THIAZOLIDINONES AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
WO2011022667A3 (en) Catalytic domains from lysyl oxidase and loxl2
WO2003089619A3 (en) Placental derived stem cells and uses thereof
WO2007031877A3 (en) Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
WO2007117438A3 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2004039957A3 (en) Inhibition of gene expression using rna interfering agents
WO2009044294A3 (en) Means and methods for the treatment of cataract and presbyopia
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
WO2004001013A3 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
ATE536745T1 (en) COMPOSITION WITH ARAZYM FOR THE PREVENTION AND TREATMENT OF CANCER
ATE522540T1 (en) SHORT INTERFERING RIBONUCLEIC ACIDS FOR THE TREATMENT OF ALLERGY DISEASES
WO2004017949A3 (en) Prophylaxis and treatment of infectious diseases
WO2006128089A3 (en) Compositions and methods for treating tissue
WO2011118928A3 (en) Pharmaceutical composition for preventing or treating heart failure and method for screening agent for preventing or treating heart failure
BRPI0507083A (en) process for preparing l-amino acids using strains from the enterobacteriaceae family
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
EA200801807A1 (en) NEW OXIDODRUCTASES AND THEIR APPLICATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08835485

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08835485

Country of ref document: EP

Kind code of ref document: A2